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Due to new genetic insights, etiologic classification of dia-
betes is under constant scrutiny. Hundreds, or even thou-
sands, of genes are linked with type 2 diabetes. Three com-
mon variants (Lys23 of KCNJ11, Pro12 of PPARG, and the
T allele at rs7903146 of TCF7L2) have been shown to be
predisposed to type 2 diabetes mellitus across many lar-
ge studies. Individually, each of these polymorphisms is
only moderately predisposed to type 2 diabetes. On the
other hand, monogenic forms of diabetes such as MODY
and neonatal diabetes are characterized by unique clinical
features and the possibility of applying a tailored treatment.
Genetic polymorphisms in drug-metabolizing enzymes,
transporters, receptors, and other drug targets have been
linked to interindividual differences in the efficacy and
toxicity of a number of medications. Mutations in genes
important in drug absorption, distribution, metabolism
and excretion (ADME) play a critical role in pharmaco-
genetics of diabetes.
There are currently five major classes of oral pharmaco-
logical agents available to treat type 2 diabetes: sulfonyl-
ureas, meglitinides, metformin (a biguanide), thiazolidi-
nediones, and a-glucosidase inhibitors. Other classes are
also mentioned in literature.
In this work, different types of genetic mutations (muta-
tions of the gene for glucokinase, HNF 1a, HNF1b and
Kir6.2 and SUR1 subunit of KATP channel, PPAR-g, OCT1
and OCT2, cytochromes, direct drug-receptor (KCNJ11),
as well as the factors that influence the development of
the disease (TCF7L2) and variants of genes that lead to
hepatosteatosis caused by thiazolidinediones) and their
influence on the response to therapy with oral antidia-
betics will be reviewed.
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INTRODUCTION
Type 2 diabetes genes
Diabetes mellitus has reached epidemic proportions and affects more than 170 mil-
lion individuals worldwide. Some 90 % of diabetic individuals have type 2 (non-insu-
lin-dependent) diabetes mellitus, and within this category no more than 10 % account
for monogenic forms (1). In 1999, a classification of diabetes based on the etiology of in-
dividual types was proposed by the Experts Committee of the World Health Organiza-
tion, and is now commonly accepted. Etiologic classification was gradually extended in
the last decade with the progress of knowledge, in particular with the successes of re-
searchers in the field of genetics (2). The detailed human genome sequence information
now available will lead to identification of more candidate genes for type 2 diabetes. De-
spite several major family and population studies, the intervals linked with type 2 dia-
betes are large and may contain hundreds, or even thousands, of genes. More than 60
potential candidate genes involved in insulin action, insulin secretion and adipose me-
tabolism (since both obesity and lipoatrophy are linked to diabetes) have been examined
in the search for type 2 diabetes susceptibility genes. Although variants have been iden-
tified in many of these, only a few have been shown to be associated with diabetes or
impaired protein function. Thus, mutations or polymorphisms that cause only modest
deficits in gene/protein function may become clinically significant when coupled with
other genetic or acquired defects. The resulting imperfect correlation between the geno-
type and phenotype makes the task of finding diabetogenes a formidable one (3).
Type 2 diabetes is a typical complex, polygenic disease for which several common
risk alleles have been identified. Three common variants (Lys23 of KCNJ11, Pro12 of
PPARG, and the T allele at rs7903146 of TCF7L2) have been shown to be predisposed to
type 2 diabetes mellitus across many large studies. Individually, each of these polymor-
phisms is only moderately predisposed to type 2 diabetes (4). Thus far, most of the suc-
cess in defining type 2 diabetes genes (diabetogenes) has been achieved by studying re-
latively rare forms of the disease (3).
Monogenic forms of diabetes are characterized by unique clinical features and the
possibility of applying a tailored treatment, assuring optimal correction of the geneti-
cally conditioned metabolic defect. Differential diagnostics of the diseases types is play-
ing an increasing role in diabetology, since it enables selection of optimal treatment
methods, as well as assessment of the prognosis of the diabetes course and occurrence of
complications (2).
Since 1992, numerous genetic subtypes of diabetes have been described in which
gene mutations result in diabetes primarily through b-cell dysfunction. This knowledge
means that patients who were previously categorized clinically as having maturity-on-
set diabetes of the young (MODY), permanent neonatal diabetes mellitus (PNDM) or
transient neonatal diabetes mellitus (TNDM) can mostly be classified by genetic sub-
group. Identification of the genetic subgroup can result in appropriate treatment, genetic
counseling and prognostic information. MODY used to be clinically defined as autoso-
mal, dominantly inherited, non-insulin-dependent, early-onset diabetes, but now there
are at least eight genetic subgroups of MODY, most of which have a discrete phenotype
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(5). These eight genetic subgroups of MODY include HNF4A, GCK, HNF1A, HNF1B,
NEUROD1, KLF11, CEL and PAX4 subtypes (6).
Diabetes diagnosed before 6 months of age is likely to be one of the monogenic forms
of neonatal diabetes (5). Neonatal diabetes mellitus can be either transient (TNDM) or
permanent (PNDM) (7, 8). TNDM is a developmental disorder of insulin production that
resolves postnatally and accounts for 50 to 60 % of cases of neonatal diabetes. In PNDM,
insulin secretory failure occurs in the late fetal or early post-natal period and does not go
into remission (9). The genetic origin has been established for more than 90 % of TNDM
cases. The majority of cases (68 %) are due to abnormalities in the 6q24 region, whereas
10 and 13 % of cases are attributable to mutations in KCNJ11 and ABCC8, respectively.
Ten genes involved in pancreatic development, b-cell apoptosis, or dysfunction have been
identified as being able to give rise to PNDM (8).
Pharmacogenetics and pharmacogenomics
Clinical observations of inherited differences in drug effects were first documented
in the 1950s, giving rise to the field of pharmacogenetics, and later pharmacogenomics.
Although the two terms are synonymous for all practical purposes, pharmacogenomics
uses genome-wide approaches to elucidate the inherited basis of differences between in-
dividuals in their response to drugs (10). Pharmacogenetics originated as a result of the
observation that there are clinically important inherited variations in drug metabolism.
However, similar principles apply to clinically significant inherited variation in the
transport and distribution of drugs and their interaction with their therapeutic targets
(11). Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and
other drug targets have been linked to interindividual differences in the efficacy and to-
xicity of a number of medications. Pharmacogenomic studies are rapidly elucidating the
inherited nature of these differences in drug disposition and effects, thereby enhancing
drug discovery and providing a stronger scientific basis for optimizing drug therapy on
the basis of each patient’s genetic constitution (12).
Among many potential causes of adverse drug reactions, genetic variants that cause
susceptibility to a drug reaction stand out. Identification of such variants is expected to
improve the management of patient care by determining which patients should avoid a
specific drug and which patients should take a modified dose of the drug. This strategy
could potentially reduce medical costs and improve the process of drug development
(13).
Drug-induced liver injury (DILI) is a major reason for regulatory actions against mar-
keting approval, removal from the place and restrictions to prescribing indications. Risk
factors for DILI involve polymorphisms in two major categories of genes: the highly
polymorphic genes in the major histocompatibility locus on chromosome 6, which en-
code antigen-presenting proteins; and various polymorphic genes that encode drug me-
tabolizing enzymes (14).
The existence of large population differences with small intrapatient variability is
consistent with inheritance as a determinant of drug response it is estimated that genet-
ics can account for 20 to 95 percent of variability in drug disposition and effects (10, 15).
Unlike other factors influencing drug response, inherited determinants generally re-
main stable throughout a person’s lifetime (10).
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PHARMACOGENETICS OF ORAL ANTIDIABETICS
There are currently five major classes of oral pharmacological agents available to
treat type 2 diabetes.
Sulfonylureas, insulin secretogogues, close the ATP-sensitive potassium channel (KATP)
on the plasma membrane. First generation sulfonylureas (acetohexomide, chlorpropami-
de, tolazamide, and tolbutamide) possess lower binding affinity for the ATP-sensitive
potassium channel and thus require higher doses to achieve efficacy. Second generation
sulfonylureas, including glyburide (glibenclamide), glipizide, gliclazide and glimepiri-
de, are now widely used. The second generation sulfonylureas are much more potent
compounds (~100-fold), possess a more rapid onset of action, and generally have shorter
plasma half-lives and longer duration of action compared to the first generation agents
(16).
Meglitinides (repaglinide, nateglinide) are a novel class of non-sulfonylurea insulin
secretogogues characterized by very rapid onset and abbreviated duration of action (17).
They stimulate first-phase insulin release in a glucose-sensitive manner, theoretically re-
ducing the risk of hypoglycemic events (16).
Metformin (a biguanide) has a glucoregulatory effect only in the presence of endoge-
nous insulin by decreasing endogenous glucose production and reducing peripheral re-
sistance to insulin (approximately 20–30 %) (17). It also increases the utilization of glu-
cose and most likely decreases appetite (18). The European Association for the Study of
Diabetes (EASD) guidelines recommend metformin as initial pharmacotherapy for type
2 diabetes (19).
Thiazolidinediones (pioglitazone, rosiglitazone – withdrawn from the the EU market
in September 2010 because of an increased cardiovascular risk) are insulin sensitizing
compounds. They have glucose- and lipid-lowering activity. They are selective agonists
for the peroxisome proliferator-activated receptor g (PPARg) and exhibit a characteristic
delay from 4–12 weeks in the onset of their therapeutic benefits. These compounds de-
crease insulin resistance and enhance the biological response to endogenously produced
insulin, as well as insulin administered by injection (16). The European Medicines Agen-
cy today recommends suspension of marketing authorizations for the rosiglitazone-con-
taining antidiabetes medicines.
a-Glucosidase inhibitors (acarbose and miglitol) block the enzymatic degradation of
complex carbohydrates in the small intestine. These compounds lower post-prandial glu-
cose and improve glycemic control without increasing the risk for weight gain or hypo-
glycemia (16).
The development pipeline for new oral therapeutic agents for type 2 diabetes is en-
couraging and continues to expand. Thus, there are new approaches like dipeptidyl pep-
tidase IV (DPP-IV) inhibition and selective cannabinoid-1 receptor (CB-1) antagonism (16).
Glucagon-like peptide 1 mimetics and amylin mimetics are also mentioned in literature
(20). Identification of the underlying molecular genetics opens the possibility of under-
standing the genetic architecture of clinically defined categories of diabetes, new biologi-
cal insights, new clinical insights, and new clinical applications (21). Understanding the
pathways that result in b cell dysfunction at physiological and molecular levels is critical
for improved understanding and treatment of type 2 diabetes.
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Rare types of diabetes in which a single gene defect results in severe b cell dysfunc-
tion offer a chance to gain new insights into this disease if the responsible gene can be
defined (22). Monogenic b-cell disorders, which are clinically recognized as MODY or
neonatal diabetes, are good examples that the therapeutic response both reflects and im-
proves our understanding of pathophysiology. Examples of these diseases illustrate how
different etiology of damage of b-cells can react very differently to therapy. The greatest
attention is paid to mutations of the genes for glucokinase, HNF 1a, HNF1b and Kir6.2
subunit of KATP channel of b-cell (23). The number of researches related to different
genes that influence the emergence of diabetes and parallel researches to investigate
pharmacogenetical parameters and factors affecting the response of the body to applied
medicines is constantly growing (Fig. 1). Researchers pay attention to genetic variations
that affect the drug ADME (absorption, distribution, metabolism, excretion), where OCT1,
cytochromes, direct drug-receptor (KCNJ11) are the factors that influence the develop-
ment of the disease (TCF7L2) (20).
Mutations in the glucokinase gene
Thus far, about 200 glucokinase (GCK) mutations have been reported (24). Patients
with heterozygous glucokinase mutations do not need any treatment, because they have
only mild hyperglycemia, as reflected in the hemoglobin A1c (HbA1c) level that is at or
slightly above the upper limit of normal (23). Both the severity of the GCK mutation and
the genetic background seem to play a relevant role in the GCK MODY phenotype (25).
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Fig. 1. Pharmacogenetics of oral antidiabetics.
Heterozygous, inactivating mutations in the glucokinase gene result in life-long mild
fasting hyperglycemia, which deteriorates very little with age. This is primarily due to
compensation through overexpression of the normal, nonmutated allele (23).
Diabetes due to mutations in glucokinase appears to be relatively mild, as indicated
by the number of affected subjects who did not have overt diabetes and by the fact that
the disease was treated by the diet alone in most subjects. The fact that most were lean,
having a normal body weight was sufficient to maintain fasting plasma glucose concen-
trations around 125 mg per deciliter (6.9 mmol L–1) (26).
Mutations in the HNF1a gene
Subjects with mutations in the HNF-1a gene usually develop diabetes in adolescen-
ce or early adulthood (27, 28). Mutations in HNF-1a result in progressive b-cell dysfunc-
tion with increasing treatment requirements and a higher risk of complications with age
(29). Deterioration of fasting glucose with age is a result of a faster deteriorating b-cell
function with the HNF-1a than with the GCK mutation (27).
Progressive b-cell failure leads to increasing hyperglycemia due to reduced insulin
secretion in response to hyperglycemia (28). The ability of glucose to induce closure of
KATP channels in the HNF-1a (–/–) mouse b-cells is significantly reduced. Since the
KATP current is blocked by the addition of ATP and NADH to the cell, the failure to gene-
rate ATP appears to account for reduced glucose responsiveness of the KATP channel in
HNF-1a (–/–) mouse b-cells (30).
Studies in b-cell models investigated the impact of human HNF-1a mutations on
b-cell function. The most common mutation of HNF-1a has dominant negative effects
on the expression of genes involved in glucose transport and glycolysis. Also, it has been
discovered that there is a common mitochondrial defect substained by diminished ATP
generation and substrate oxidation (31). This form of diabetes frequently requires treat-
ment with oral agents or insulin (27).
Sulfonylureas can dramatically improve glycemic control and should be considered
as the initial treatment for patients with poor glycemic control on an appropriate diet
(32). Marked sensitivity to the hypoglycemic effect of sulfonylureas in HNF-1a subjects
has been observed, which could be explained, at least in part, by increased insulin sensi-
tivity (27, 28, 33). The key feature of all these defects is that they are upstream of the
KATP channel. This means that as long as some ATP is present within the b-cell, sulfony-
lureas would be able to close the channel, because this is downstream of the primary de-
fect. This explains why these patients are sensitive to the hypoglycemic effects of sul-
fonylureas, but does not explain the progressive deterioration in b-cell function that re-
sults in increasing hyperglycemia with age. The precise mechanisms of chronic reduc-
tion in b-cell mass are uncertain (23).
Glibenclamide is one of the most widely used orally active sulfonylureas in the treat-
ment of type 2 diabetes. Hypoglycemia is the most important and most often fatal ad-
verse effect of sulfonylureas (34).
In studies of the HNF1a knockout animals, researchers hypothesized that the redu-
ced clearance of glibenclamide was due to a decrease in hepatic uptake or impaired me-
tabolism of the sulfonylurea. Hypoglycemia may occur more frequently in subjects with
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HNF-1 a deficiency treated with glibenclamide because of delayed disappearance of the
drug from the blood. Very low doses of short-acting sulfonylureas should therefore be
used initially in the treatment of patients with HNF-1a deficiency, and these drugs should
be discontinued in subjects with liver disease. Monitoring sulfonylurea plasma concen-
tration in HNF-1a deficiency patients may also be useful for avoiding hypoglycemia (34).
Cessation of sulfonylureas should be undertaken cautiously as there may be marked de-
terioration in glycemic control (32).
In a randomized crossover trial of gliclazide and metformin in 36 patients, either
with diabetes caused by HNF-1a mutations or type 2 diabetes, who were matched for
body-mass index and fasting plasma glucose, Pearson et al. (33) found that patients with
HNF-1a diabetes had a stronger response to gliclazide than to metformin and also stron-
ger response to gliclazide than those with type 2 diabetes. Patients with HNF-1a diabe-
tes had a strong insulin secretory response to intravenous tolbutamide despite a weak
response to intravenous glucose, and were more insulin sensitive than those with type 2
diabetes. Sulfonylurea metabolism was similar in both patient groups.
Mutations in the HNF-1a gene make up the majority of cases that might be mis-
taken for type 1 diabetes (35, 36).
One study was made on eight UK Caucasian patients with median age of 34 years
(range 17–48), median age of diagnosis 14 years (range 8–17), and median time on insu-
lin 20 years (range 4–35); four patients had been on insulin for more than 27 years. All
patients were able to discontinue insulin and were maintained on sulfonylureas without
developing ketonuria or marked hyperglycemia. There was heterogeneity in response of
the majority of patients (6 of 8), showing an improvement in control. In short-term studies,
when patients with HNF-1a mutations were transferred from insulin to sulfonylureas,
good glycemic control was achieved, even when patients had been on prolonged insulin
treatment before transferring. These preliminary short-term data needs to be repeated in
larger series with long-term follow-up. Many of these patients may require insulin again
in the future (37).
Mutations in the HNF1b gene
The syndrome of mild diabetes mellitus, progressive non-diabetic renal disease and
severe genital tract abnormalities with vaginal aplasia and rudimentary uterus are asso-
ciated with a heterozygous mutation in the HNF-1b gene (38). The low insulin sensitivity
in HNF-1b subjects suggests that an insulin sensitizer such as metformin or a peroxi-
some proliferator-activated receptor-g agonist would be the oral agent of choice. HNF-1b
patients have a different diabetes phenotype than HNF-1a patients. The difference in both
the pancreatic and extrapancreatic phenotypes of HNF-1a and HNF-1b mutations is strik-
ing, particularly in view of the close homology of these transcription factors and their
shared binding site (39). It was found that HNF-1b defines a cellular population that forms
primitive pancreatic ducts. Such embryonic duct HNF-1b+ cells are phenotypically dis-
tinct from earlier pancreatic bud cells and present evidence that they are direct precur-
sors of endocrine progenitor cells (40).
There are no useful models of the role of HNF-1b in the b-cell because the
HNF-1b–/– mouse dies at an early embryonic stage and there is no published literature
on HNF-1b in pancreatic cell lines (39). Despite considerable homology of HNF-1a and
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HNF-1b, differences in associated diabetes phenotypes exist in MODY. Despite the evi-
dence suggestive of insulin resistance, insulin requirements in patients with diabetes due
to HNF-1b tend to be low. These low requirements could indicate that patients still have
considerable endogenous insulin secretion. This suggests that the b-cell defects in dia-
betic subjects caused by HNF-1b mutations are qualitatively different from HNF-1a with
different sites or severity of defects. In HNF-1b mutation carriers diabetes may develop
during embriogenesis, a consequence of which is reduced b-cell mass. HNF-1b patients do
not respond particularly well to sulfonylureas, and this is consistent with the PEAKtolb-
-to-PEAKgluc ratio being similar to type 2 diabetes (39).
Mutations in the gene for Kir6.2 (KCNJ11) and SUR1 (ABCC8)
To date, more than 30 heterozygous, activating mutations in KATP channels have been
reported (41). KATP channel is composed of four small subunits Kir6.2 that surround the
central cavity and four major subunits that build SUR1 (42). Every subunit can be in opened
and closed conformation (43). Numerous factors can modulate the activity of KATP chan-
nels. This can happen at the level of Kir6.2 and SUR subunits. The most important fac-
tors that inhibit the Kir6.2 are ATP and ADP, and the most important factors that inhibit
SUR are sulfonylureas. The most important factors that activate Kir6.2 are fatty acid me-
tabolites, PIP2 (phosphatidylinositol phosphate) and SUR diazoxide, Mg-ATP and Mg-
-ADP. Glucose and amino acids can regulate the secretion of insulin. Glucose and amino
acids are metabolized in b cells in which ATP is created, which leads to closure of KATP
channels, accumulation of intracellular potassium, membrane depolarization, opening
voltage dependent calcium channel that stimulates insulin exocytosis (42).
KCNJ11 (coding Kir6.2 subunit of KATP channel) mutations that cause a small de-
crease in the ATP sensitivity of heterozygous KATP channels result in neonatal diabetes
alone, whereas those which produce a greater reduction in ATP-sensitivity are associ-
ated with additional symptoms. The molecular mechanism by which a mutation affects
the channel ATP sensitivity determines the severity of its effect in the heterozygous sta-
te, with the mutations that influence gating producing larger effects on ATP sensitivity,
and a more severe disease phenotype, than those that lie in the putative ATP-binding
site (44). Of the 49 patients with heterozygous activating mutations in the KCNJ11 gene,
who were treated with an adequate dose of sulfonylureas, 44 were able to stop insulin
treatment. The switch to sulfonylureas was successful regardless of the type of sulfony-
lurea used, suggesting a class effect (45). Efficacy of sulfonylurea therapy is likely to de-
pend on the nature of the Kir6.2 mutation. Functional characterization of additional mu-
tations in Kir6.2, as well as additional clinical studies, will provide essential data regard-
ing the efficacy of sulfonylurea therapy in treating KATP-induced diabetes and the possi-
bility of tailoring individual therapy based on the underlying Kir6.2 mutation. Careful
attention should be paid to the degree to which neonatal diabetes mutations cause a loss
of ATP sensitivity by an increase in open-state stability. The greater is the mutational ef-
fect on open-state stability, the higher will be the sulfonylurea dose necessary to achieve
a given degree of channel inhibition. Thus, to achieve the same therapeutic effect (suffi-
cient closure of KATP under appropriate physiological conditions), proportionally higher
doses of an sulfonylurea may be clinically required. Models of the KATP channel gating
and nucleotide and sulfonylurea sensitivity have been developed. To have predictive
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use, such models should account for channel gating (in the absence of ATP), nucleotide
sensitivity, and drug sensitivity, and by adjusting relevant parameters, they should be
able to account for the effects of mutations on channel function (46).
Heterozygous activating mutations in ABCC8, encoding the SUR1 regulatory sub-
unit of the ATP-sensitive potassium channels found in beta cells, cause both permanent
and transient neonatal diabetes. Although molecular mechanisms of the ABCC8 and
KCNJ11 mutations are distinct, the cellular mechanism reducing insulin release is com-
mon to both. Treatment with sulfonylureas, glyburide or glipizide was initiated in pa-
tients with permanent neonatal diabetes and transient neonatal diabetes and has proved
effective (47). Oral sulfonylurea therapy is safe and effective for a short term in most pa-
tients with diabetes due to SUR1 mutations and may successfully replace treatment with
insulin injections. A different treatment protocol needs to be developed for this group of
patients because they require lower doses of sulfonylureas than those required by Kir6.2
patients (48).
Zung et al. (49) observed near-normal postprandial glucose values although gliben-
clamide administration was not synchronized with meals, which contained significant
amounts of simple carbohydrates. This overcame the initial concern that sulfonylurea the-
rapy might result in unregulated insulin secretion, because sulfonylurea receptor 1-me-
diated KATP channel closure might prevent the channel from responding to altered ATP
concentrations resulting from varying glucose concentrations through the classical pathway.
Sulfonylureas cause partial closure of the KATP channel, which means that the b-cell
membrane is no longer fully depolarized, and is therefore able to respond to other stim-
uli, particularly glucagon-like peptide-1, which is released with food. Additional studies
are needed, but early results strongly support the idea that incretins and other alterna-
tive pathways that stimulate insulin secretion are required for excellent glycemic control
(23).
According to pharmacokinetic data, chronic glibenclamide treatment in vivo causes
loss of insulin secretory capacity due to b-cell hyperexcitability, but also reveals rapid re-
versibility of this secretory failure, arguing against b-cell apoptosis or other cell death in-
duced by sulfonylureas. These in vivo studies may help explain why patients with type 2
diabetes can show long-term secondary failure to secrete insulin in response to sulfony-
lurea, but experience restoration of insulin secretion after a drug resting period, without
permanent damage to b-cells. This finding suggests that novel treatment regimens may
succeed in prolonging pharmacological therapies in susceptible individuals (50).
The common E23K polymorphism in KCNJ11 has been most extensively studied in
the classical form of type 2 diabetes. E23K variant in the candidate gene KCNJ11 may im-
pair insulin secretion stimulated by sulfonylureas, thus increasing the risk of developing
secondary failure to these oral agents (51).
Mutations of the cytochrome p450 system
The polymorphic enzyme cytochrome P450 (CYP) 2C9 is the main enzyme that cata-
lyzes the biotransformation of sulfonylureas (52). Although not the most prominent risk
factor, CYP2C9 genotypes predictive of low enzyme activity (CYP2C9*3/*3 and *2/*3) should
be considered as one but not the main risk factor for severe hypoglycemia resulting from
treatment with sulfonylurea oral hypoglycemic agents. Furthermore, comedication with
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agents that inhibit CYP2C9 might be an additional risk factor for hypoglycemia by in-
creasing the concentrations of oral hypoglycemic drugs that are metabolized by this en-
zyme. Genotyping of CYP2C9 allelic variants is a relatively easy and inexpensive test
that might help prevent adverse reactions to CYP2C9 substrates (53).
Pharmacokinetics of glyburide depended significantly on CYP2C9 genotypes. In
homozygous carriers of genotype *3/*3, total oral clearance was less than half that of the
wild-type genotype *1/*1. The corresponding differences in insulin plasma levels indi-
cated that dose adjustment based on CYP2C9 genotype may improve antidiabetic treat-
ment (54).
Tolbutamide was confirmed as a substrate of the genetically polymorphic enzyme
CYP2C9. The pronounced differences in pharmacokinetics due to amino acid variants
did not significantly affect plasma insulin and glucose concentrations in healthy volun-
teers (55).
The meglitinide class drug nateglinide is metabolized by CYP2C9. According to phar-
macokinetic data, moderate dose adjustments based on CYP2C9 genotypes may help in
reducing interindividual variability in the anti hyperglycemic effects of nateglinide (52).
Significantly reduced oral nateglinide clearance was found in carriers of CYP2C9*3 al-
leles, whereas carriers of CYP2C9*2 alleles had kinetic parameters similar to those of the
wild-type allele carriers. Carriers of the CYP2C9*3/*3 genotype may be at a slightly hi-
gher risk of hypoglycemia compared to carriers of CYP2C9*1, particularly when taking
nateglinide doses above 120 mg (56).
Repaglinide is metabolized by CYP2C8 and, according to clinical studies, CYP2C8*3
carriers had higher clearance than carriers of the wild-type genotypes; however, this was
not consistent with in vitro data and therefore further studies are needed. CYP2C8*3 is
closely linked with CYP2C9*2 (52). An association of insulin-like growth factor 2 mRNA-
-binding protein 2 (IGF2BP2) rs1470579 and rs4402960 polymorphisms and development
of type 2 diabetes, and therapeutic efficacy of repaglinide in Chinese type 2 diabetes pa-
tients was reported (57).
Bozkurt et al. (58) published 37 studies between 1966 and 2007 reporting data on ge-
netic polymorphisms and responses to glucose-lowering drugs. Most studies involving
cytochrome P450 (CYP) genes had small sample sizes (21 studies < 50 subjects) and in-
cluded healthy volunteers. They found that CYP2C9*3 allele was associated with a de-
creased clearance of meglitinides.
CYP2C8 and CYP3A4 are the main enzymes that catalyze biotransformation of the
thiazolidinediones troglitazone and pioglitazone, whereas rosiglitazone is metabolized
by CYP2C9 and CYP2C8.
Pharmacogenetic variability plays an important role in the pharmacokinetics of oral
antidiabetic drugs; however, the impact of this variability on clinical outcomes in pa-
tients is still mostly unknown and prospective studies on the medical benefit of CYP ge-
notyping are required (52).
Mutations in the OCT1 and OCT2 gene
OCT1 deletion results in reduced metformin uptake and response in primary mouse
hepatocytes. OCT1 appears to play a key role in determining one of the major pharmaco-
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logic effects of metformin, inhibition of hepatic gluconeogenesis. OCT1 polymorphisms
modulate metformin uptake and response in cells. Seven OCT1 variants exhibited re-
duced metformin uptake compared to the OCT1-reference. The tissue-specific action of
metformin may be related to expression of influx transporters such as OCTs that can de-
liver metformin intracellularly (59).
Liver concentration of metformin was approximately 30 times higher in Oct1(+/+)
mice than Oct(–/–) mice. A 3- to 7-fold higher distribution in Oct1(+/+) than in Oct(–/–)
mice was also observed in the duodenum, jejunum, and ileum. On the other hand, the
distribution of metformin to the kidney was almost identical for the two types of mice
and the difference in the distribution to the colon was minimal (60). Metformin is domi-
nantly transported by OCT2 compared to OCT1. The in vivo tissue uptake clearance of
metformin in male rat kidney was about 6 times higher than that in male liver, and the-
refore the plasma flow rate in the kidney might be a limiting factor for metformin renal
distribution (61).
Mutations in the TCF7L2 gene
Pearson et al. (62) studied the influence of variation within TCF7L2 on the early re-
sponse to sulfonylureas and metformin in 1,846 patients with type 2 diabetes in Tayside,
Scotland. Variation in TCF7L2 influences the initial treatment success with sulfonylurea
therapy in patients with type 2 diabetes. This is seen for both SNPs (rs12255372 and
rs7903146) that were reported to be associated with diabetes risk and is an addition to
the effect of dose, adherence, sex, and baseline glycemia. Compared with the monogenic
examples, the effect of TCF7L2 variation on the response is modest, although a twofold
greater likelihood of treatment failure in 12% of the population who are TT homozygote
at rs1225372 is striking.
There was a weak association between metformin treatment success and TCF7L2 ge-
notype. This study is a robust example of pharmacogenetics within an unselected poly-
genic type 2 population (62).
Mutations in the PPARG gene
Five haplotype blocks in PPARG and its surrounding regions were identified, and
association results based on the response to troglitazone suggests that three of these may
independently, or jointly, be involved in mediating the response to troglitazone. Individ-
ual SNPs in blocks 1, 3, and 5, plus SNP rs1152003, showed association with 3-month
changes in phenotypes, suggesting that these regions may be of importance in mediating
troglitazone response. Sequence variation in PPARG that may contribute to different in-
sulin-sensitizing responses to troglitazone therapy in Hispanic women with previous ge-
stational diabetes was identified (63). Genetic variants within two haplotype blocks may
help determine the response. Whether the inability to respond to troglitazone therapy is
due to an effect of these variants on troglitazone binding to PPARG or an impairment of
the agonistic activity of troglitazone through disruption of interactions between PPARG
and critical PPARG cofactors (e.g., retinoid X receptor-a) will require functional charac-
terization studies. Response to thiazolidinediones therapy may not be accurately predic-
ted by genotyping one or two variants within PPARG. Instead, prediction of the response
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may require assessment of a cluster of genotypes, possibly across different genes. None-
theless, our results provide the first evidence supporting the concept that variation wi-
thin PPARG partly accounts for the response to therapy with thiazolidinediones (63).
The Pro12Ala variant in the PPARG gene does not affect the efficacy of pioglitazone
therapy, suggesting that the drug-treatment response is independent of pharmacogene-
tic effects between PPARG and its ligand pioglitazone. Whether the Ala12Ala genotype
plays a role in the response rate to thiazolidinedione therapy remains to be determined
(64).
Among young Hispanic women at high risk of type 2 diabetes, the Pro12Ala variant
of the PPARG receptor gene did not explain the failure of 1/3 of subjects to increase their
insulin sensitivity when placed on troglitazone at a dose of 400 mg/day (65).
Peroxisome proliferator activated receptor-g coactivator-1a (PGC-1a) Thr394Thr and
Gly482Ser polymorphisms were associated with the therapeutic efficacy of multiple-do-
se rosiglitazone in Chinese patients with type 2 diabetes mellitus (66).
Variants of genes that lead to hepatosteatosis caused by thiazolidinediones
Obesity-associated diabetes (diabesity) also has a complex polygenic basis in mice.
Admixing genomes of unrelated strains of inbred mice provides an insight into how a
complex disease such as type 2 diabetes can become more common as genetic heteroge-
neity increases in an outbreeding human population. A panel of recombinant congenic
strains (RCSs) with varying degrees of obesity and diabetes was generated. Availability
of the panel of genetically characterized RCS models of diabesity with differential thia-
zolidinedione sensitivities is useful for understanding the genetic basis for susceptibility
to adverse drug responses. Such pharmacogenetic knowledge might distinguish a small
percentage of patients who should not take this class of compounds. RCS8 and RCS10
exhibit comparable levels of obesity and basal hepatic lipidosis with a control diet, but
only RCS8 experiences a drug-exacerbated steatosis as extreme as originally described
in F1. The most notable genetic difference distinguishing RCS8 is its NZO (New Zealand
obese) origin of chromosome 16 in its entirety. The cholinephosphate cytidylyltransfera-
se-a subunit is encoded on this chromosome. The active form of cholinephosphate cytidy-
lyltransferase activity resides on cellular membranes. Subcellular fractionation showed
that rosiglitazone-mediated reduction in the cholinephosphate cytidylyltransferase ac-
tivity in total homogenate was primarily in a cytosol and, to a lesser extent, in the crude
mitochondrial fraction. Genetic disruption of cholinephosphate cytidylyltransferase-a
(CTa) produces a hepatic phenotype similar to that observed in rosiglitazone-treated F1
(67). In studies on mice in which the hepatic CT a gene was specifically inactivated it
was observed that impairment in the hepatic CDP-choline pathway alters the metabo-
lism of both hepatic and circulating lipids and lipoproteins (68). In RCS8, not only is
cholinephosphate cytidylyltransferase activity reduced, but also this partial loss of choli-
nephosphate cytidylyltransferase activity is accompanied by significant losses in both
choline kinase and PEMT (phosphatidylethanolamine methyltransferase) biosynthetic
functions. At least four other loci on chromosome 16 associated with hepatic triglyceride
metabolism and steatosis represent potential candidates. Rosiglitazone-mediated inhibi-
tion of enzymes in both arms of the phosphatidylcholine biosynthetic pathway would
very likely impair lipoprotein assembly and export, and hence promote, the observed
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hepatic triglyceride accumulation. Moreover, regardless of the mechanism of the decrea-
se in cholinephosphate cytidylyltransferase and PEMT activity as a result of rosiglitazo-
ne treatment, less diacylglycerol would be used in the biosynthesis of phosphatidylcho-
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Table I. Mutations of genes that can affect treatment with oral antidiabetics





Marked sensitivity to hypoglycemic effect of sulfonylureas (27, 28,
33). Transferring insulin-treated patients with HNF-1a mutations to
sulfonylureas was safe for a short term (37).
HNF-1b Do not respond particularly well to sulfonylureas (39).
KCNJ11
Of the 49 patients with heterozygous activating mutations in the
KCNJ11 gene who were treated with an adequate dose of
sulfonylureas, 44 were able to stop insulin treatment. The switch to
sulfonylureas was successful regardless of the type of sulfonylurea
used (45). Efficacy of sulfonylurea therapy is likely to depend on
the nature of the Kir6.2 mutation (46).
KCNJ11, E23K variant
May impair insulin secretion stimulated by sulfonylureas, thus in-
creasing the risk to develop secondary failure to these oral agents
(51).
ABCC8
Oral sulfonylurea therapy is safe and effective for a short term in




CYP2C9*3/*3 and *2/*3 should be considered as one but not the
main risk factor for severe hypoglycemia resulting from treatment
with sulfonylurea oral hypoglycemic agents (53).
TCF7L2 (rs12255372
and rs7903146)
Influences initial treatment success with sulfonylurea therapy in pa-
tients with type 2 diabetes (62).
Meglitinides
CYP2C9*3 Significantly reduced oral nateglinide clearance (56).
CYP2C8*3
Repaglinide is metabolized by CYP2C8 and, according to clinical
studies, CYP2C8*3 carriers had higher clearance than carriers of the
wild-type genotypes (52).
IGF2BP2 Mutations can affect treatment with repaglinide treatment (58).
Metformin
OCT1
Deletion results in reduced metformin uptake and response in pri-
mary mouse hepatocytes (59).
Thiazolidinediones
PPARG
SNPs in blocks 1, 3, and 5, plus SNP rs1152003, showed association
with 3-month changes in phenotypes, suggesting that these regions
may be of importance in mediating troglitazone response (63).
PGC-1a Mutations can affect treatment with rosiglitazone (66).
line. Under such conditions, the diacylglycerol would be acylated to triacylglycerol and
this could lead to the observed hepatic steatosis. It remains to be established whether
this unusual pharmacogenetic effect is mediated via direct effects of peroxisome proli-
ferator-activated receptor-g (PPAR g) at the hepatocyte or indirectly by primary drug ef-
fects on another tissue, such as white fat. These results indicate a constitutive impair-
ment of hepatic phosphatidylcholine biosynthetic enzyme functions, which is further
exacerbated by thiazolidinedione treatment (67).
Other mutations that can affect therapy with oral antidiabetics
There have lately been new reports on polymorphisms that can influence therapy
with oral antidiabetics. Carriers of A allele of Thr394Thr had high density lipoprotein-
-cholesterol, which was enhanced to a lesser degree and lower attenuated postprandial
serum insulin compared to G alleles. Patients with PGC-1a Gly482Gly had fasting plasma
glucose that was attenuated to a greater degree and postprandial serum insulin compa-
red to Gly482Ser+Ser482Ser. After rosiglitazone treatment, carriers of A allele of Thr394Thr
and Ser allele of Gly482Ser showed a worsening trend for GG and a significant therapeu-
tic response to rosiglitazone for Gly/Gly. Huang et al. (68) found that the effects of repa-
glinide treatment on fasting plasma glucose (p < 0.05) and postprandial plasma glucose
(p < 0.05) were reduced in patients with the rs1470579 AC+CC genotypes compared to
AA genotype carriers. Patients with the rs4402960 GT+TT genotypes exhibited an en-
hanced effect of repaglinide.
Table I shows summarized mutations of genes that can affect treatment for each phar-
macologic group of antidiabetic drugs.
CONCLUSIONS
Numerous genes that influence pharmacogenetics of oral antidiabetics have been
discovered to date. The number of new conclusions regarding individual therapy of dia-
betes is growing every day. Particularly interesting area of oral antidiabetics is the im-
portance of accurate dosage to prevent hypoglycemia and use of wrong medicines. With
the development of pharmacogenetics it is easier for patients to cope with this disease
and new opportunities for therapeutic improvement are provided. However, further re-
search is needed in the field.
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S A @ E T A K
Geneti~ki polimorfizmi u dijabetesu: Utjecaj na terapiju oralnim antidijabeticima
UNA GLAMO^LIJA i ADLIJA JEVRI]-^AU[EVI]
Dijabetes tipa 2 dosegao je proporcije epidemije u SAD (> 18 milijuna) i cijelom
svijetu (170 milijuna oboljelih osoba) te ima tendenciju daljnjeg dramati~nog rasta. Stoga
se u posljednje vrijeme ula`u napori da se otkriju i razviju novi farmakolo{ki agensi za
lije~enje ove bolesti. Klasifikacija {e}erne bolesti pro{irena je uspjesima istra`iva~a na
podru~ju genetike. Da bismo razumjeli farmakogenetiku antidijabetika neophodno je ra-
zumjeti genetiku samog dijabetesa. Kao {to }e biti prikazano u ovom radu veliki broj ge-
na koji su povezani s razvojem dijabetesa tako|e utje~e i na odgovor na terapiju antidija-
beticima. S druge strane, mutacije gena koji utje~u na ADME (apsorpcija, distribucija,
metabolizam i ekskrecija) lijeka imaju zna~ajan utjecaj na farmakogenetiku oralnih anti-
dijabetika.
Utvr|eno je da je dijabetes geneti~ki heterogena bolest. Uobi~ajeni oblici dijabetesa
su gotovo uvijek poligenski i za razvoj same bolesti vrlo su zna~ajne sna`ne interakcije
me|u razli~itim genima kao i izme|u gena i okoli{a. Zbog toga mutacije ili polimorfizmi
koji u manjoj mjeri utje~u na funkciju gena mogu postati klini~ki zna~ajni samo u slu~aju
kada se kombiniraju s drugim faktorima odnosno genima. Smatra se da u razvoju dija-
betesa mogu sudjelovati stotine pa ~ak i tisu}e gena. Do 2006. identificirano je nekoliko
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uobi~ajenih alela koji pove}avaju rizik za razvoj dijabetesa, od kojih su najzna~ajniji PPARG
(Pro12), KCNJ11 (Lys23) i TCF7L2 (T na rs7903146). Do danas je najve}i uspjeh postignut
u identifikaciji gena odgovornih za razmjerno rijetke oblike ove bolesti poput »Matu-
rity-onset diabetes of the young« (MODY) i neonatalnog dijabetesa. Monogenske oblike
dijabetesa odlikuju jedinstvene klini~ke karakteristike i mogu}nost primjene individual-
nog tretmana.
Geneti~ki polimorfizmi enzima koji utje~u na metabolizam lijekova, transportera, re-
ceptora i drugih ciljeva djelovanja lijekova povezani su s interindividualnim razlikama
u efikasnosti i toksi~nosti mnogih lijekova. Vrlo je va`no da se na temelju farmakogene-
ti~kih istra`ivanja mogu predvidjeti neki ne`eljeni efekti lijekova.
Trenuta~no postoji pet glavnih klasa oralnih antidijabetika: sulfoniluree, meglitini-
di, metformin (bigvanid), tiazolidindioni i inhibitori a-glukozidaze. U literaturi se tako-
|er spominju inhibitori dipeptidil peptidaze IV (DPP-IV), selektivni antagonisti kanabi-
noidnog receptora 1 (CB-1), mimetici glukagonu sli~nog peptida 1 i mimetici amilina.
Razumijevanje mehanizama koji rezultiraju disfunkcijom b stanica na fiziolo{kom i
molekularnom nivou neophodno je za napredak u razumijevanju tretmana dijabetesa. U
ovom radu dat je pregled razli~itih geneti~kih mutacija (mutacije gena za glukokinazu,
HNF 1a, HNF1b, Kir6.2 i SUR 1 podjedinicu KATP kanala b stanica, PPAR-g, OCT1 i OCT2,
citohrome, KCNJ11, faktore koji utje~u na razvoj bolesti (TCF7L2) i varijante gena koji
dovode do hepatosteatoze uzrokovane tiazolidindionima) te njihov utjecaj na odgovor
na terapiju oralnim antidijabeticima.
Klju~ne rije~i: farmakogenetika, oralni antidijabetici
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